
Akifumi Nakamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10066197/publications.pdf Version: 2024-02-01



AKIELIMI NAKAMIIDA

#	Article	IF	CITATIONS
1	Prevalence and profile of depressive mixed state in patients with autism spectrum disorder. Psychiatry Research, 2021, 300, 113932.	3.3	1
2	A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash. Therapeutic Drug Monitoring, 2020, 42, 631-635.	2.0	5
3	>Development of the 12-item questionnaire for quantitative assessment of depressive mixed state (DMX-12). Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1983-1991.	2.2	5
4	Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy. Therapeutic Drug Monitoring, 2019, 41, 86-90.	2.0	13
5	Serum creatine kinase elevation by atypical antipsychotics and genetic polymorphisms of the 5-HT2A receptor and the cytochrome P450 2D6: a preliminary finding. Clinical Neuropsychopharmacology and Therapeutics, 2018, 9, 3-6.	0.3	1
6	Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder. Neuropsychobiology, 2017, 75, 145-150.	1.9	11
7	A Partial Response at Week 4 Can Predict Subsequent Outcome during Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder: A Preliminary Study. Neuropsychobiology, 2017, 76, 187-192.	1.9	2
8	Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2. Therapeutic Drug Monitoring, 2016, 38, 379-382.	2.0	10
9	Lamotrigine augmentation therapy in a case with treatmentâ€resistant unipolar depression that showed insufficient response to electroconvulsive therapy. Psychiatry and Clinical Neurosciences, 2016, 70, 126-126.	1.8	2
10	Lack of Correlation Between the Steady-State Plasma Concentrations of Aripiprazole and Haloperidol in Japanese Patients With Schizophrenia. Therapeutic Drug Monitoring, 2014, 36, 815-818.	2.0	10
11	Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients. Clinical Neuropsychopharmacology and Therapeutics, 2010, 1, 1-5.	0.3	5
12	Pharmacokinetic and Pharmacodynamic Interactions Between Carbamazepine and Aripiprazole in Patients With Schizophrenia. Therapeutic Drug Monitoring, 2009, 31, 575-578.	2.0	36